#AAN2018: New Data Largely Supports Memantine Combo Easing Alzheimer’s Symptoms

#AAN2018: New Data Largely Supports Memantine Combo Easing Alzheimer’s Symptoms
New data on how Allergan’s Namenda (memantine) — given in combination with cholinesterase inhibitors — works to help ease some symptoms of Alzheimer's disease will be presented at the American Academy of Neurology annual meeting in Los Angeles, April 21-27. The data, the results of five studies supported by Allergan, will be presented through scientific posters on April 27 at the conference, which Alzheimer's News Today is covering remotely. Namenda works by blocking the action of a natural substance (glutamate) in the brain. Although it does not cure Alzheimer's disease, it may improve memory, awareness, and the ability to perform daily functions. Namenda, alone or in combination with a cholinesterase inhibitor (ChEI) — such as Aricept (donepezil) — has been shown to improve global and cognitive functions in Alzheimer’s patients. Increasing evidence supports that Namenda-ChEI combination therapy brings more clinical benefits than monotherapy with either drug or drug class. The studies being presented involved post-hoc (after-the-fact) analysis on the data of several randomized clinical trials. Two studies focused on the cognitive function of Alzheimer’s patients — assessed through the
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *